Believes Truly Independent Board Required
to Increase Accountability Given PharmaCyte's Long History of
Missed Milestones
Highlights Severe Governance Deficiencies
and Recent Half-Baked Efforts to Appease Stockholders
Nominates Seven Experienced Highly
Qualified Director Nominees
NEW
YORK, June 23, 2022 /PRNewswire/ -- Iroquois
Capital Management, LLC (together with its affiliates, "Iroquois"),
one of the largest stockholders of PharmaCyte Biotech, Inc.
("PharmaCyte" or the "Company") (NASDAQ:PMCB) with beneficial
ownership of approximately 6.1% of the outstanding common stock of
the Company, today announced that it has nominated a slate of seven
(7) highly qualified director candidates for election to the
PharmaCyte Board of Directors at the Company's upcoming 2022 annual
meeting of stockholders. Iroquois also announced that it has
publicly delivered a letter to the Company's stockholders making
clear the case for a significant reconstitution of the Board with
professionals possessing the requisite skillsets, experience, drive
and sense of accountability needed to turn the Company around.
The full text of the letter follows:
June 23, 2022
Dear Fellow PharmaCyte Biotech Stockholders:
As previously communicated, Iroquois Capital Management, LLC
(together with its affiliates, "Iroquois") currently owns
approximately 6.1% of the outstanding shares of PharmaCyte Biotech,
Inc. ("PharmaCyte" or the "Company"), making us one of the
Company's largest stockholders.
We invested in the Company in August
2021 due to our belief in the promise of its proprietary
cellulose-based live cell encapsulation technology and the
potential for its use as an innovative platform upon which cellular
therapies for several types of cancer and diabetes can be based
upon. However, like many of you, we have grown weary of the
repeated delays, shifting timelines and missed milestones with
respect to the lifting of the clinical hold imposed on the
Company's Phase 2b clinical trial for
pancreatic cancer therapy that PharmaCyte's management team and
Board of Directors (the "Board") have repeatedly communicated, both
publicly in its press releases and privately during the course of
the past six months in our attempt to engage constructively with
the Board regarding our concerns.
The Company's most recent press release has done nothing to
change what appears to be a habituated practice by PharmaCyte's
leadership to deflect accountability and kick the can further down
the road with no definitive plan to create value for its patient
stockholders who have been forced to endure a severe destruction of
their investment. For instance, it is still not clear based on the
Company's latest communication what more is required of the Company
to respond to the FDA concerning its inquiries surrounding the
clinical hold.
Moreover, we take issue with the Company's attempts to minimize
our concerns with PharmaCyte's stock price underperformance, poor
investor communication, dismal corporate governance practices and
lack of alignment with stockholders as a "distraction" as we
strongly believe it downplays how widely our dissatisfaction is
shared among the Company's stockholders.
Only now in response to our public letters to the Board and
communicated intention to nominate director candidates for election
at the Company's 2022 Annual Meeting of Stockholders (the "Annual
Meeting") did the Company deem it appropriate to announce a stock
buyback and implement quarterly earnings conference calls, each of
which occurred after our public suggestions and private
recommendations over the course of the past six months, and concede
that the Board lacks directors with sufficient capital markets
experience. However, we have yet to see any admission by the
Company of the root causes of the issues surrounding the Company, a
chummy Board that is comprised of individuals, the majority of whom
are physicians who lack any capital markets or public company
directorship experience apart from PharmaCyte, and each of whom has
been hand-picked by Kenneth L.
Waggoner, the Company's Chairman and Chief Executive
Officer, and has never purchased a single share of the Company in
the open market.
We believe this strategy is nothing but a reactive and
transparent attempt to demonstrate an openness to change while the
underlying goal is clearly to defend the status quo and make as
little change as possible to appease stockholders. To that end, we
note that the Company's statement that it has been rebuffed in its
offers to review our nominees is a false characterization of our
attempts to work in good faith to reach a mutually agreeable
resolution with the Board. We have been clear with the Company that
the Board must be materially reconstituted with stockholder
representatives and the Board's unwillingness to recognize this
meaningful amount of change required instead reflects its desire to
ensure that its incumbents, whom we believe to be beholden to Mr.
Waggoner, remain in place while minimizing the number of truly
independent directors.
Furthermore, we find it disingenuous that the Company has
referenced new executive compensation agreements as evidence of
leadership's alignment with the Company's stockholders while
avoiding to make such agreements, and the goals upon which cash and
equity bonuses for its executives are tied thereunder, public for
the benefit of all stockholders until the filing of its Annual
Report on Form 10-K in mid-July. Far from being the Company's
"common practice", not only is this the first time that PharmaCyte
will be filing a Form 10-K as a Nasdaq-listed company, in
April 2022, the Board found it
material to disclose on Form 8-K the base compensation payable in
cash to Mr. Waggoner and Carlos
Trujillo, the Company's Chief Financial Officer, less than
one week after such arrangements were made. If the Company's new
executive compensation arrangements are truly designed to align
management's interests with that of the Company's stockholders, why
has the Company only deemed it material to disclose the cash
component of such compensation packages when it could just as
easily disclose the equity incentives contained therein and assuage
stockholder concerns?
While the Company's press release makes a point of patting
leadership on the back for raising $90
million in three weeks while the market was experiencing a
state of euphoria, we believe this overshadows the over ten years
in which PharmaCyte has suffered as a barely known and little-loved
penny stock, and believe stockholders will see through the façade
of a Board puppeteering to be hard at work to represent stockholder
interests. While anyone can get lucky, we strongly believe
management and the Board are not even qualified to manage the funds
on the Company's balance sheet, and will be eagerly awaiting the
filing of its Form 10-K in mid-July to determinate whether the
Company has availed itself of any cash management systems to earn
interest on such funds, which at this point, given the earnings
that can accrue on investments in the U.S. Treasury market, could
actually cover most of the Company's entire projected cash burn on
a quarterly basis. To the extent such a simple action readily
within the Board's control has not been taken to generate
stockholder returns, we believe it will become even more apparent
that not one individual on the Board, including its Chief Financial
Officer who serves thereon in contravention to well established
corporate governance practices, possesses the requite
qualifications to manage any of the Company's finances in a
fiduciary manner, let alone nearly $90
million.
As one of the largest stockholders of the Company, we believe
the status quo is untenable, and a change of tone at the top
through a material reconstitution of the Board is urgently needed
for the Company to turn over a new leaf for the benefit of all
PharmaCyte stockholders. For this reason, we are nominating seven
(7) exceptional, experienced and highly-qualified nominees for
election to the Board at the Annual Meeting, including two direct
Iroquois representatives. We believe stockholders deserve a Board
that is unburdened by past loyalties, welcomes fresh viewpoints and
demands accountability so that the Company can maximize its
incredible potential. Iroquois has a long history of driving
operational, financial, strategic and governance changes for the
benefit of all stockholders. We firmly believe that with the right
Board in place, PharmaCyte can fulfill the promise many
stockholders have in the Company's science and generate significant
value for all stockholders.
We are confident the professionals we have nominated are
incredibly well-qualified to serve as directors of PharmaCyte. This
group of extremely impressive director candidates has backgrounds
spanning drug development, intellectual property, capital markets,
investment banking, strategic transformation and public company
governance. As a group, they have substantial and highly successful
experience in the pharmaceutical, biotechnology and broader
healthcare industries. Collectively, they have decades of
experience as CEOs, senior executives, chairmen and directors of
well-performing biotechnology and pharmaceutical companies. It is
clear to us that direct representation of stockholders is needed,
especially in light of the Board's half-hearted attempts to appease
stockholders without addressing the root causes of the Company's
issues – its dysfunctional Board. For the benefit of other
PharmaCyte stockholders, we have included detailed biographies of
our nominees in an appendix to this letter.
Our goal is to represent the best interests of all stockholders
and we believe our actions will place the Company on a path to
greater accountability and stockholder returns. We remain confident
in our belief that PharmaCyte has tremendous unmet potential that
can be unlocked through improved governance and the addition of
experienced professionals to the Board with the requisite
skillsets, experience, drive and sense of accountability needed to
turn the Company around. While we will continue to attempt to work
constructively with the Board to find a mutually agreeable
solution, we also look forward to further engagement with our
fellow stockholders and will be sharing additional information
about our views on PharmaCyte and ideas for significant value
creation.
Best Regards,
/s/ Richard Abbe
Richard Abbe
Managing Member
Iroquois Capital Management, LLC
Biographies of Iroquois' Nominees
Richard Abbe
We believe Mr. Abbe's position as a significant investor
in the Company and his extensive strategic, financial, capital
markets and corporate governance experience and prior public
company board experience make him an ideal director candidate for
the Board. Mr. Abbe has served as the Co-founder, Principal
and Managing Partner of Iroquois Capital Management, LLC, an
investment advisory firm to certain privately pooled and highly
active investment funds, since 2003. Mr. Abbe has also served as
Co-Chief Investment Officer of such funds since their inception in
2003. From 2000 to 2003, Mr. Abbe co-founded and served as Co-Chief
Investment Officer of Vertical Ventures, LLC, a merchant bank.
Prior to 2000, he was employed by Lehman Brothers Holdings Inc.
where he rose through the ranks in its Equity Middle Market
Institutional Sales department. From 1998 to 1999, Mr. Abbe served
as a Senior Managing Director at Gruntal & Co., L.L.C., a
boutique investment bank where he was responsible for its
Institutional Sales and Trading desk and served on the firm's Board
of Directors. From 1994 to 1998, he served as a Founding Partner at
Hampshire Securities Corporation, a boutique investment bank which
was sold to Gruntal & Co., L.L.C. in 1998. Mr. Abbe's
professional experience includes his service served on the Boards
of Directors of XpresSpa Group, Inc. (formerly Vringo Inc.), a
health and wellness company, from March
2016 to December 2018, and
National Holdings Corporation, a financial services provider, from
July 2014 to September 2016. He served on the Board of
Trustees of Hobart and William Smith
Colleges, in addition to his roles as Vice Chairman of
Endowments and member of the Investment Committee of the Hobart
College Endowment. He received his B.A. in Economics from
Hobart University.
Stephen Friscia
We believe Mr. Friscia's more than twenty years of
experience as an investment professional and expertise in analyzing
and working directly with management teams on the businesses,
strategic initiatives and corporate governance philosophies of his
portfolio companies would make him a valuable addition to the
Board. Mr. Friscia is a private investor and serves as the
manager and co-founder of Kipps Capital, a family office with
interests in publicly traded equity securities, private equity
securities and real estate holdings, since January 2016. Prior to the creation of his family
office, Mr. Friscia served as an institutional small and mid-cap
value equity portfolio manager for over 15 years including as
Managing Director and Portfolio Manager of Iridian Asset Management
LLC, a value-oriented investment management firm focused on active
equity investment strategies, from 2009 to 2016, MacKay Shields
LLC, an investment management firm, from 2008 to 2009, Bear Stearns
Asset Management Inc., formerly the asset management business of
The Bear Stearns Companies, Inc., from 2006 to 2008, and as a
Portfolio Manager at John A. Levin & Co., Inc., an investment
advisory firm, from 2003 to 2006, and Evergreen Investments LLC,
formerly the investment management business of Wachovia
Corporation, from 1993 to 2003. Mr. Friscia earned his B.S. in
Business Administration from the State
University of New York at New Paltz and his M.B.A. in
Finance from Pace University.
Charles S. Ryan, Ph.D.
We believe Dr. Ryan's more than 25 years of senior
executive experience in the biotechnology and pharmaceuticals
industry, including as a chief executive officer, chief
intellectual property counsel and member of the board of directors
of both public and private biotechnology companies, in addition to
his expertise in capital acquisition, intellectual property, due
diligence investigations, drug development, investor relations and
strategic planning well qualifies him to serve on the
Board. Dr. Ryan has served as President, Chief Executive
Officer and Chairman of the Board of Directors of Travecta
Therapeutics, Inc., a private biotechnology company developing
treatments for serious neurological conditions through a platform
designed to deliver drugs across the blood brain barrier, since
May 2021. Dr. Ryan served as Chief
Executive Officer of Neurotrope, Inc. (n/k/a Synaptogenix,
Inc.), a clinical-stage biopharmaceutical company with a pipeline
of technology to treat various neurodegenerative diseases, from
February 2018 to December 2020, and served as a member of its
board of directors from December 2017
to December 2020. From October 2016 to February
2018, he served as President and Chief Executive Officer for
the Orthobond Corporation, a private company focused on creating
proprietary surface modifications for the medical device,
biotechnology and pharmaceutical industries to enhance the function
of a device or pharmaceutical. From March
2015 to May 2016, Dr. Ryan
served as Vice President and General Counsel at Cold Spring Harbor
Laboratory, a non-profit institution focused on neuroscience,
bioinformatics, cancer, genomics and plant biology. From 2003 to
2014, Dr. Ryan served as Senior Vice President and Chief
Intellectual Property Counsel for Forest Laboratories, Inc., a
specialty pharmaceutical company whose most significant drugs were
Lexapro® and Namenda®. Dr. Ryan began his career in biotechnology
with The Collaborative Group, Ltd., a bioscience company providing
development, research and manufacturing services to the
pharmaceutical and skin care industries, where he was the Vice
President, General Counsel, from 1998 to 2002. Dr. Ryan also has
experience in private law practice, having held positions with
Darby & Darby, P.C. and Scully, Scott, Murphy & Presser. He
previously served as a member of the board of directors of Applied
DNA Sciences, Inc., a provider of molecular-based supply chain
authentication and security solutions, from August 2011 to November
2019, and BioRestorative Therapies, Inc., a life sciences
company, from April 2015 to
January 2020. His experience also
includes directorships held at ABS Materials, Inc., Lab21, Inc.,
GlycoMira Therapeutics, Inc., Forest Laboratory Holdings, Ltd., the
Board of Trustees for The College of
Wooster, New York Biotechnology Association, Stony Brook
University Medical Center Development Council (Chair) and Western
New England University Board of
Trustees. Dr. Ryan earned his B.A. in Chemistry from The
College of Wooster, a Ph.D. in Oral
Biology and Pathology from Stony
Brook University and his J.D. from Western New England University.
Jonathan L. Schechter
We believe Mr. Schechter's experience as a public company
director in addition to his unique skillsets gained from working
with public companies for over two decades, including ten years of
legal experience and fourteen years of investment banking
experience, would make him a valuable addition to the
Board. Mr. Schechter has served as Partner of The Special
Equities Group, a division of Dawson James Securities, Inc., a full
service investing firm specializing in healthcare, biotechnology,
technology, and clean-tech sectors, since April 2021. From May
2019 to March 2021, Mr.
Schechter served as Director of Bradley
Woods & Co. Ltd., a registered broker-dealer. He served
as the Director of Investment Banking at Chardan Capital
Markets LLC, a full service investment firm specializing in
healthcare and disruptive innovation companies, from
February 2008 to May 2018. From
2005 until 2007, Mr. Schechter served as the general counsel for a
hedge fund specializing in PIPE transactions and structured
products. From 1999 until 2005, Mr. Schechter worked as a corporate
associate at Bryan Cave LLP specializing in representing companies,
investors and investment banks in general corporate matters
including PIPE and merger/acquisition transactions. Mr. Schechter's
professional experience includes his service on the Board of
Directors of Neurotrope, Inc. (n/k/a Synaptogenix, Inc.), a
clinical-stage biopharmaceutical company with a pipeline of
technology to treat various neurodegenerative diseases, since
December 2018, and DropCar, Inc. (n/k/a Ayro, Inc.), a
company that develops automotive based products and services, from
March 2017 to January 2018. Mr. Schechter earned his A.B.
in Public Policy/Political Science from Duke
University and his J.D. from Fordham
University School of Law.
Joshua N. Silverman
We believe Mr. Silverman's extensive experience as an
investment banker, management consultant and as a chairman and
director of numerous public companies within the biotechnology and
pharmaceutical industries would be extremely additive to the
Board. Mr. Silverman has served as the managing member of
Parkfield Funding LLC, an investment management firm specializing
in pharmaceutical and biotechnology companies, since 2013.
Mr. Silverman served as a Co-Founder, Principal and Managing
Partner of Iroquois Capital Management, LLC, an investment advisory
firm to certain privately pooled and highly active investment
funds, and as Co-Chief Investment Officer of such funds, from 2003
until July 2016. From 2000 to 2003,
Mr. Silverman co-founded served as Co-Chief Investment Officer of
Vertical Ventures, LLC, a merchant bank. Prior to that, Mr.
Silverman served as a director of Joele
Frank, Wilkinson, Brimmer, Katcher LLC, a boutique
consulting firm specializing in mergers and acquisitions, and as
Assistant Press Secretary to the President of the United States. Mr. Silverman currently
serves on the Boards of Directors of Petros Pharmaceuticals, Inc.,
a men's health pharmaceutical company, since December 2020, MyMD Pharmaceuticals, Inc.
(formerly Akers Biosciences, Inc.), a clinical stage pharmaceutical
company, since September 2018, Ayro,
Inc. (formerly DropCar, Inc. and WPCS International
Incorporated), an electric vehicle design and manufacturing
company, since August 2016,
Synaptogenix, Inc. (formerly Neurotrope, Inc.), a
clinical-stage biopharmaceutical company with a pipeline of
technology to treat various neurodegenerative diseases, since
August 2016, and Protagenic
Therapeutics, Inc. (formerly Atrinsic, Inc.), a biotechnology
company, since February 2016. He
previously served as a director of National Holdings Corporation, a
financial services provider, from July
2014 through August 2016, and
as a director of Marker Therapeutics, Inc.(formerly TapImmune
Inc.), from August 2016 until
October 2018. Mr. Silverman received
his B.A. in Political Science from Lehigh
University.
Kimberly Page
We believe Mrs. Page's position as a steward of capital
invested in the Company combined with her over twenty years of
experience in finance, risk management, auditing, compliance,
institutional operations and capital markets make her an ideal
director candidate for the Board. Mrs. Page currently
serves as Chief Operating Officer and Compliance Officer of
Iroquois Capital Management, LLC, an investment advisory firm to
certain privately pooled and highly active investment funds, which
she joined in 2001, and as a Director of Iroquois Master Fund Ltd.
In her role, Mrs. Page overseas business operations, hedge fund
domestic and international regulatory compliance, preparation of
monthly net asset value calculations, coordinating with fund
administrator and auditors, filings with securities regulators and
monitoring of fund strategies including distressed debt,
multi-currency, long/short equities, arbitrage, private equity,
options, and delta hedging. Prior to 2001, Mrs. Page was employed
by Instinet.com ("Instinet"), a leading electronic trading exchange
platform launching a competitor to E-Trade prior to Instinet's
initial public offering in 2001, reporting to the Head of Business
Development. Mrs. Page received her B.S. in Marketing from the
University of Massachusetts.
Jude C. Uzonwanne
We believe Mr. Uzonwanne's experience as a corporate
strategy and transaction services adviser in the healthcare and
industrials sector, his understanding of complex commercial and
mergers and acquisitions transactions, and his experience working
with emerging biotech and traditional pharmaceutical clients in key
global life sciences markets well qualifies him to serve on the
Board. Mr. Uzonwanne served as Chief Business Officer
at 54gene, Inc. ("54gene"), a clinical-stage biopharmaceutical
company, from March 2021 to
June 2022. Prior to his role at
54gene, Mr. Uzonwanne served as a Principal at ZS Associates, Inc.
("ZS Associates"), a consulting and professional services firm
focusing on consulting, software and technology that provides
services for clients in the private equity, healthcare, and
technology industries, from January
2021 to March 2021. Prior to
joining ZS Associates, he served as a Principal at IQVIA Holdings
Inc. ("IQVIA"), a clinical research and health information
technology company, from 2018 to 2020, where he served as the head
of the firm's US Financial Investors Consulting practice and as
management consulting lead for IQVIA's service to a top-6 global
pharmaceutical company and select emerging biopharmaceutical
companies. His professional experience also includes his service as
Vice President (Associate Partner) at EY-Parthenon LLP, a global
strategy consulting firm, from 2016 to 2018; Principal (Associate
Partner) at Bain & Company, Inc., a global strategy consulting
firm, from 2015 to 2016; Associate Partner at Dalberg Global
Development Advisers, a strategy and policy advisory firm, in 2015;
and Deputy Director, Strategy, of the Bill and Melinda Gates
Foundation, from 2013 to 2015. He has also served in several senior
leadership roles at Overseas Shipholding Group, Inc., as Assistant
Vice President, Corporate Development, from 2007 to 2009, Monitor
Group LLP (now Monitor Deloitte LLP), a global strategy consulting
firm, from 1998 to 2011 and Nirsal Plc, a wholly owned agricultural
credit insurance subsidiary of the Central Bank of Nigeria, as an advisor and founding Chief
Executive Officer and Managing Director, from 2011 to 2013. Mr.
Uzonwanne has served as a member of the boards of directors of MyMD
Pharmaceuticals, Inc., a clinical stage pharmaceutical company,
since April 2021, and Bonita Foods
Nigeria Limited, a privately held emerging market specialty food
and snacks company, since August
2019. Mr. Uzonwanne earned his B.A. in Economics and
Political Science from Swarthmore College.
About Iroquois Capital Management, LLC
Iroquois
Capital Management, LLC is a New
York-based investment adviser that provides investment
advisory services to Iroquois Master Fund Ltd., a privately pooled
investment vehicle.
Certain Information Concerning the
Participants
Iroquois Master Fund Ltd., a Cayman Island
exempted limited company ("Iroquois Master"), together with the
other participants named herein (collectively, "Iroquois"), intends
to file a preliminary proxy statement and accompanying WHITE proxy
card with the Securities and Exchange Commission ("SEC") to be used
to solicit votes in connection with the 2022 annual meeting of
stockholders of PharmaCyte Biotech, Inc., a Nevada corporation (the "Company").
IROQUOIS STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO
READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH
PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB
SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS
PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT
WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES
SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.
The participants in the proxy solicitation are anticipated to be
Iroquois Master, Iroquois Capital Management, LLC, a Delaware limited liability company ("Iroquois
Capital"), Iroquois Capital Investment Group LLC, a Delaware limited liability company ("ICIG"),
Richard Abbe, Kimberly Page, Stephen
Friscia, Charles S. Ryan,
Johnathan L. Schechter, Joshua N. Silverman and Jude C. Uzonwanne.
As of the close of business on June 22,
2022, , Iroquois Master is the direct beneficial owner of
(i) 1,190,421 shares of common stock, par value $0.0001 per share (the "Common Stock") and (ii)
196,000 shares of Common Stock issuable upon the exercise of
certain warrants, all of which are subject to a 4.99% blocker
provision (the "Warrants"). As of the close of business on
June 22, 2022, ICIG is the direct
beneficial owner of (i) 68,370 shares of Common Stock and (ii)
84,000 shares of Common Stock issuable upon the exercise of
Warrants. Iroquois Capital, as the investment manager to Iroquois
Master, may be deemed the beneficial owner of the (i) 1,190,421
shares of Common Stock and (ii) 196,000 shares of Common Stock
issuable upon the exercise of the Warrants directly owned by
Iroquois Master. As of the close of business on June 22, 2022, Mr. Abbe does not directly
beneficially own any securities of the Company. Mr. Abbe, by virtue
of his position as the President of Iroquois Capital and as a
managing member of ICIG, may be deemed the beneficial owner of the
(i) 1,258,791 shares of Common Stock and (ii) 280,000 shares of
Common Stock issuable upon the exercise of the Warrants owned in
the aggregate by Iroquois Master and ICIG. As of the close of
business on June 22, 2022, Mrs. Page
does not directly beneficially own any securities of the Company.
Mrs. Page, by virtue of her position as a Director of Iroquois
Master, may be deemed the beneficial owner of the (i) 1,190,421
shares of Common Stock and (ii) 196,000 shares of Common Stock
issuable upon the exercise of the Warrants directly owned by
Iroquois Master. As of the close of business on June 22, 2022, Messrs. Friscia, Ryan, Schechter,
Silverman and Uzonwanne do not own beneficially or of record any
securities of the Company.
Investor Contact
Richard
Abbe
Managing Member
Iroquois Capital Management, LLC
(212) 974-3070
View original
content:https://www.prnewswire.com/news-releases/iroquois-capital-nominates-slate-of-highly-qualified-director-candidates-for-election-at-pharmacytes-2022-annual-meeting-301574084.html
SOURCE Iroquois Capital Management, LLC